RecruitingEarly Phase 1NCT06497361

Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease

Studying IgG4-related disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tongji Hospital
Principal Investigator
Lingli Dong
Tongji Hospital
Intervention
PRG-2311(biological)
Enrollment
30 enrolled
Eligibility
18 years · All sexes
Timeline
20242028

Study locations (1)

Collaborators

Shenzhen Pregene Biopharma Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06497361 on ClinicalTrials.gov

Other trials for IgG4-related disease

Additional recruiting or active studies for the same condition.

See all trials for IgG4-related disease

← Back to all trials